Cathie Wood and Ark Invest sold roughly $7,379,804 worth of Palantir stock — and spent $9,145,824 on three biotech stocks.

Biotech stock Halozyme Therapeutics is climbing back in constructive form from a severe drop in November. Shares got a boost after the drug-delivery developer reiterated its 2024 forecast and raised ...

Analysts at HC Wainwright increased their FY2024 earnings per share estimates for shares of Evaxion Biotech A/S in a note issued to investors on Monday, February 3rd. HC Wainwright analyst S.

Learn more about whether Catalyst Pharmaceuticals, Inc. or Ionis Pharmaceuticals, Inc. is a better investment based on AAII's ...

Oncolytics Biotech (ONCY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Faced with the encroaching threats of patent expirations and generics, biopharma companies in 2024 invested 33% more in ...

Learn more about whether Alkermes plc or Vericel Corporation is a better investment based on AAII's A+ Investor grades, which ...

Shares of Amgen (AMGN) fell in after-hours trading after the biotechnology company reported earnings for its fourth quarter ...

Amgen reported strong fourth-quarter earnings, driven by strategic acquisitions and robust product sales growth.

CSL Ltd ( ASX: CSL) shares will be closely watched by Aussie investors next week. That's because the biotechnology giant is ...

Vertex Pharmaceuticals ( VRTX 2.53%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs ...

Tommy Hilfiger and Calvin Klein owner PVH (PVH) and biotechnology company Illumina (ILMN) were among the first casualties on the American side ...